Suppr超能文献

循环RNA分子作为肝脏疾病的生物标志物

Circulating RNA molecules as biomarkers in liver disease.

作者信息

Enache Liviu S, Enache Elena L, Ramière Christophe, Diaz Olivier, Bancu Ligia, Sin Anca, André Patrice

机构信息

Université de Lyon, Université Lyon 1, Lyon F-69008, France.

University of Medicine and Pharmacy Tirgu Mures, 38 Gh. Marinescu st., Tirgu Mures 540142, Romania.

出版信息

Int J Mol Sci. 2014 Sep 30;15(10):17644-66. doi: 10.3390/ijms151017644.

Abstract

Liver disease is a major cause of morbidity and mortality worldwide. As in other fields of medicine, there is a stringent need for non-invasive markers to improve patient diagnostics, monitoring and prognostic ability in liver pathology. Cell-free circulating RNA molecules have been recently acknowledged as an important source of potential medical biomarkers. However, many aspects related to the biology of these molecules remain to be elucidated. In this review, we summarize current concepts related to the origin, transportation and possible functions of cell-free RNA. We outline current development of extracellular RNA-based biomarkers in the main forms of non-inherited liver disease: chronic viral hepatitis, hepatocellular carcinoma, non-alcoholic fatty liver, hepato-toxicity, and liver transplantation. Despite recent technological advances, the lack of standardization in the assessment of these markers makes their adoption into clinical practice difficult. We thus finally review the main factors influencing quantification of circulating RNA. These factors should be considered in the reporting and interpretation of current findings, as well as in the proper planning of future studies, to improve reliability and reproducibility of results.

摘要

肝脏疾病是全球发病和死亡的主要原因。与医学的其他领域一样,迫切需要非侵入性标志物来提高肝脏病理学中患者诊断、监测和预后评估的能力。无细胞循环RNA分子最近被认为是潜在医学生物标志物的重要来源。然而,与这些分子生物学相关的许多方面仍有待阐明。在本综述中,我们总结了与无细胞RNA的起源、运输和可能功能相关的当前概念。我们概述了非遗传性肝病主要形式(慢性病毒性肝炎、肝细胞癌、非酒精性脂肪肝、肝毒性和肝移植)中基于细胞外RNA的生物标志物的当前进展。尽管最近技术取得了进步,但这些标志物评估缺乏标准化使得它们难以应用于临床实践。因此,我们最后回顾了影响循环RNA定量的主要因素。在报告和解释当前研究结果以及合理规划未来研究时,应考虑这些因素,以提高结果的可靠性和可重复性。

相似文献

1
Circulating RNA molecules as biomarkers in liver disease.
Int J Mol Sci. 2014 Sep 30;15(10):17644-66. doi: 10.3390/ijms151017644.
2
Circulating liver-specific microRNAs as noninvasive diagnostic biomarkers of hepatic diseases in human.
Biomarkers. 2019 Mar;24(2):103-109. doi: 10.1080/1354750X.2018.1528631. Epub 2018 Oct 23.
3
Circulating microRNAs: Possible role as non-invasive diagnostic biomarkers in liver disease.
Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):370-377. doi: 10.1016/j.clinre.2016.11.001. Epub 2016 Dec 9.
4
Exosomal miRNAs as biomarkers in the diagnosis of liver disease.
Biomark Med. 2017 May;11(6):491-501. doi: 10.2217/bmm-2017-0011. Epub 2017 Jun 9.
5
Circulating RNA: looking at the liver through a frosted glass.
Biomarkers. 2015;20(6-7):339-54. doi: 10.3109/1354750X.2015.1101785.
9
Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease.
Clin Chim Acta. 2015 Jun 15;446:267-71. doi: 10.1016/j.cca.2015.05.002. Epub 2015 May 7.

引用本文的文献

3
Basic Understanding of Liver Transplant Immunology.
J Clin Exp Hepatol. 2023 Nov-Dec;13(6):1091-1102. doi: 10.1016/j.jceh.2023.05.007. Epub 2023 May 26.
5
Circulating messenger RNA variants as a potential biomarker for surveillance of hepatocellular carcinoma.
Front Oncol. 2022 Dec 13;12:963641. doi: 10.3389/fonc.2022.963641. eCollection 2022.
6
Nucleic acid biomarkers to assess graft injury after liver transplantation.
JHEP Rep. 2022 Jan 26;4(3):100439. doi: 10.1016/j.jhepr.2022.100439. eCollection 2022 Mar.
7
Targeting miRNA by Natural Products: A Novel Therapeutic Approach for Nonalcoholic Fatty Liver.
Evid Based Complement Alternat Med. 2021 Aug 13;2021:6641031. doi: 10.1155/2021/6641031. eCollection 2021.
8
Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues.
Ann Transl Med. 2021 Apr;9(8):730. doi: 10.21037/atm-2020-ubih-05.
9
Repression of Alleviates High-Fat Diet-Induced Hepatosteatosis by Targeting Pref-1.
Front Endocrinol (Lausanne). 2020 Nov 26;11:589994. doi: 10.3389/fendo.2020.589994. eCollection 2020.
10
Profiling the circulating mRNA transcriptome in human liver disease.
Oncotarget. 2020 Jun 9;11(23):2216-2232. doi: 10.18632/oncotarget.27617.

本文引用的文献

1
MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches.
Cell Death Differ. 2015 Jan;22(1):46-57. doi: 10.1038/cdd.2014.136. Epub 2014 Sep 5.
2
A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.
PLoS One. 2014 Aug 20;9(8):e105192. doi: 10.1371/journal.pone.0105192. eCollection 2014.
3
Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis.
Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12169-74. doi: 10.1073/pnas.1412608111. Epub 2014 Aug 4.
5
Comparison of circulating, hepatocyte specific messenger RNA and microRNA as biomarkers for chronic hepatitis B and C.
PLoS One. 2014 Mar 18;9(3):e92112. doi: 10.1371/journal.pone.0092112. eCollection 2014.
7
The complete exosome workflow solution: from isolation to characterization of RNA cargo.
Biomed Res Int. 2013;2013:253957. doi: 10.1155/2013/253957. Epub 2013 Sep 25.
8
Influence of plasma processing on recovery and analysis of circulating nucleic acids.
PLoS One. 2013 Oct 18;8(10):e77963. doi: 10.1371/journal.pone.0077963. eCollection 2013.
9
The need for transparency and good practices in the qPCR literature.
Nat Methods. 2013 Nov;10(11):1063-7. doi: 10.1038/nmeth.2697.
10
Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers.
PLoS One. 2013 Sep 20;8(9):e75184. doi: 10.1371/journal.pone.0075184. eCollection 2013.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验